Axon Enterprise (AXON) reported $575.15 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 33.1%. EPS of $2.08 for the same period compares to $1.12 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $566.07 million, representing a surprise of +1.60%. The company delivered an EPS surprise of +35.95%, with the consensus EPS estimate being $1.53.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Axon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Annual recurring revenue: $1,001 versus $940.51 estimated by two analysts on average.
- Net Sales- Software and Sensors: $353.91 million versus the five-analyst average estimate of $351.91 million. The reported number represents a year-over-year change of +30.7%.
- Revenue- TASER: $221.23 million versus $214.16 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +37.1% change.
- Net Sales- Services- Software and Sensors: $230.33 million compared to the $222.21 million average estimate based on five analysts. The reported number represents a change of +40.8% year over year.
- Net Sales- Products- Software and Sensors: $123.59 million versus $129.70 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +15.3% change.
- Net Sales- Products- TASER: $206.62 million compared to the $201.48 million average estimate based on four analysts. The reported number represents a change of +36.6% year over year.
- Net Sales- Services- TASER: $14.62 million versus $14.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +44.6% change.
- Net Sales- Products: $330.21 million versus $332.80 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +27.8% change.
- Net Sales- Services: $244.94 million versus $233.19 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +41% change.
- Net Sales- Products- TASER- Extended warranties: $10.35 million compared to the $9.07 million average estimate based on two analysts. The reported number represents a change of +25.8% year over year.
- Net Sales- Products- TASER- Other: $12.05 million compared to the $6.07 million average estimate based on two analysts. The reported number represents a change of +169.4% year over year.
- Net sales by Product- Software and Sensors segment- Axon Body: $66.26 million versus $73.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +12.4% change.
Shares of Axon have returned -17.4% over the past month versus the Zacks S&P 500 composite's -1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>Axon Enterprise, Inc (AXON) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
